Alpha 2.0
Login Register
» Authors » L F Eichenfield

L F Eichenfield

Explore the profile of L F Eichenfield including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 72
Citations 819
Followers 0
Related Specialties
Dermatology
Pediatrics
Infectious Diseases
Top 10 Co-Authors
S F Friedlander
A S Paller
B B CUNNINGHAM
J P Thyssen
P J Honig
C Vestergaard
S Barbarot
J Schmitt
A D Irvine
M Deleuran
Published In
Br J Dermatol
Pediatr Dermatol
J Am Acad Dermatol
J Eur Acad Dermatol Venereol
Pediatr Clin North Am
Affiliations
Soon will be listed here.
Recent Articles
1.
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events
Bissonnette R, Eichenfield L, Simpson E, Thaci D, Kabashima K, Thyssen J, et al.
J Eur Acad Dermatol Venereol . 2023 Jan; 37(5):976-983. PMID: 36652273
Despite the emergence of novel targeted treatments for atopic dermatitis (AD), there is a lack of guidelines on standardizing analysis of clinical trial data. To define and estimate meaningful treatment...
2.
Topical therapy of atopic dermatitis with a focus on pimecrolimus
Luger T, Paller A, Irvine A, Sidbury R, Eichenfield L, Werfel T, et al.
J Eur Acad Dermatol Venereol . 2021 Apr; 35(7):1505-1518. PMID: 33834524
Atopic dermatitis (AD) is a chronic and relapsing, inflammatory skin disease characterized by impaired skin barrier function and immune system dysregulation that results in dryness, skin microbiome dysbiosis and intense...
3.
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
Reich K, DeLozier A, Nunes F, Thyssen J, Eichenfield L, Wollenberg A, et al.
J Dermatolog Treat . 2020 Nov; 33(3):1521-1530. PMID: 33222559
Background: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient's quality of life (QoL). Objective: To evaluate the impact of baricitinib...
4.
A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force
Misery L, Belloni Fortina A, El Hachem M, Chernyshov P, von Kobyletzki L, Heratizadeh A, et al.
J Eur Acad Dermatol Venereol . 2020 Oct; 35(4):787-796. PMID: 33090558
Atopic dermatitis (AD) is a disease that can have a high impact on quality of life, especially due to itch and skin pain. This paper utilizes expertise from members of...
5.
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
Cork M, Thaci D, Eichenfield L, Arkwright P, Sun X, Chen Z, et al.
Br J Dermatol . 2020 Sep; 184(5):857-870. PMID: 32969489
Background: Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16-week, randomized, placebo-controlled, phase III trial in children, dupilumab, a...
6.
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study
Philipp S, Menter A, Nikkels A, Barber K, Landells I, Eichenfield L, et al.
Br J Dermatol . 2020 Mar; 183(4):664-672. PMID: 32173852
Background: Limited options are available for treatment of paediatric psoriasis. Objectives: To evaluate the efficacy and safety of ustekinumab in paediatric patients with psoriasis (≥ 6 to < 12 years...
7.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, et al.
Br J Dermatol . 2020 Jan; 183(2):242-255. PMID: 31995838
Background: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. Objectives: To evaluate the...
8.
The impact of airborne pollution on atopic dermatitis: a literature review
Hendricks A, Eichenfield L, Shi V
Br J Dermatol . 2019 Dec; 183(1):16-23. PMID: 31794065
The increasing prevalence of atopic dermatitis (AD) parallels a global rise in industrialization and urban living over recent decades. This shift in lifestyle is accompanied by greater cutaneous exposure to...
9.
Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial
Eichenfield L, Marcoux D, Kurvits M, Liljedahl M
J Eur Acad Dermatol Venereol . 2019 Nov; 34(5):1098-1104. PMID: 31721327
Background: Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical formulations containing corticosteroids and/or vitamin...
10.
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
Cork M, Thaci D, Eichenfield L, Arkwright P, Hultsch T, Davis J, et al.
Br J Dermatol . 2019 Oct; 182(1):85-96. PMID: 31595499
Background: Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate-to-severe atopic dermatitis (AD). Dupilumab significantly improved AD signs/symptoms in...